June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Birdshot Retinochoroidopathy: Characteristics of Patients Treated at a Tertiary Care Center
Author Affiliations & Notes
  • James Michael Samson
    Ophthalmology, Manhattan Eye Ear and Throat Institute, New York, New York, United States
    Biology, University of California San Diego, La Jolla, California, United States
  • Gabrielle Fridman
    Ophthalmology, Manhattan Eye Ear and Throat Institute, New York, New York, United States
  • Briana Glick
    Ophthalmology, Manhattan Eye Ear and Throat Institute, New York, New York, United States
  • C Michael Samson
    Ophthalmology, Manhattan Eye Ear and Throat Institute, New York, New York, United States
  • Footnotes
    Commercial Relationships   James Samson None; Gabrielle Fridman None; Briana Glick None; C Samson None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3920 – A0463. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      James Michael Samson, Gabrielle Fridman, Briana Glick, C Michael Samson; Birdshot Retinochoroidopathy: Characteristics of Patients Treated at a Tertiary Care Center. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3920 – A0463.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To describe characteristics of a cohort of patients diagnosed with Birdshot Retinochoroidopathy (BRC) at a tertiary care center.

Methods :
Retrospective chart review of patients diagnosed with BRC at the Manhattan Eye Ear, Throat Hospital from January 2017 to July 2021. Outcome measures included age of onset, HLA-A29 positivity, laterality, visual acuity and function, presence of cystoid macular edema, need for immunomodulatory therapy (IMT), and disease course.

Results :
Forty-three patients were analyzed. The average age of onset was 50.9 years and 81.4% of patients were female. Forty-two patients (97.7%) were HLA-A29 positive. All patients had bilateral involvement and were visually functional across the time frame of the study. Six patients (14.0%) were blind in one eye. Thirty-five patients (81.4%) experienced cystoid macular edema at some point in their disease. Thirty-five patients (81.4%) required IMT and 30 patients (69.8%) completed at least two years of therapy prior to discontinuing treatment. Of those, 73.3% were free of inflammation for five years, while 20% had recurrence of inflammation. Ten patients (27.9%) of the cohort remained on IMT during the course of the study.

Conclusions :
The characteristics of BRC in our cohort resembled those reported in other studies. Treatment of severe disease with IMT was associated with good visual outcome and disease remission.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×